Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769659 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
A Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence, sponsored by NeuroPro Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06769659: Recruiting Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence, sponsored by NeuroPro Therapeutics.
NCT06769659 is a Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence that is actively recruiting participants, run by NeuroPro Therapeutics. The registered enrollment target is 10 participants, below the 120-participant average among 3 other Epilepsy, Generalized trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06769659, a Phase 2 study of Epilepsy, Generalized and Epilepsy, Absence, is actively recruiting participants, sponsored by NeuroPro Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.
Primary Outcome
Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizures (defined as 2.5-6 Hz spike-wave bursts lasting greater than 3 seconds) between NPT 2042 and placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG NPT 2042
Study Locations (1)
Arkansas
- Clinical Trials, Inc. (CTI) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-05-30 |
| Phase | Phase 2 |
What NCT06769659 shows while recruiting
NCT06769659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 120-participant average among 3 other Epilepsy, Generalized trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Epilepsy, Generalized appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06769659 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT06769659 about?
NCT06769659 is a clinical study titled "A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures". This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80...
What is the current status of trial NCT06769659?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-03-11. Estimated completion is 2026-05-30.
What conditions does trial NCT06769659 study?
This clinical trial studies the following conditions: Epilepsy, Generalized, Epilepsy, Absence.
What interventions are being tested in trial NCT06769659?
The interventions under investigation include: Placebo (OTHER), NPT 2042 (DRUG).
Who is sponsoring clinical trial NCT06769659?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769659 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy, Generalized
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI